D. Neri
发表
P. Erba,
R. Slart,
F. Migliorini,
2022,
Pharmaceuticals.
G. Tortora,
C. Halin,
M. Matasci,
2022,
Journal for ImmunoTherapy of Cancer.
M. Manz,
J. Scheuermann,
S. Cazzamalli,
2022,
Chem.
A. Oxenius,
Abdullah Elsayed,
Sheila Dakhel Plaza,
2023,
mAbs.
I. Amit,
B. Becher,
A. Weiner,
2023,
Science Translational Medicine.
M. Manz,
S. Cazzamalli,
G. Bassi,
2022,
European Journal of Nuclear Medicine and Molecular Imaging.
C. Halin,
M. Manz,
J. Mock,
2023,
mAbs.
E. Gilardoni,
F. Seehusen,
T. Weiss,
2023,
Pharmaceutics.
Ian A. Watson,
Jianwen A. Feng,
S. Cazzamalli,
2023,
bioRxiv.
R. Kornberg,
N. Ban,
M. Matasci,
2023,
Nature Chemistry.
E. Gilardoni,
S. Cazzamalli,
A. Zana,
2023,
Bioconjugate chemistry.
Ian A. Watson,
Jianwen A. Feng,
S. Cazzamalli,
2023,
ACS omega.
E. Gilardoni,
R. De Luca,
E. Puca,
2023,
Antibodies.
S. Cazzamalli,
G. Bassi,
Nicholas Favalli,
2023,
European Journal of Nuclear Medicine and Molecular Imaging.
E. Gilardoni,
L. Pignataro,
S. Cazzamalli,
2023,
Frontiers in pharmacology.
K. Schäfers,
M. Weckesser,
F. Büther,
2021,
European Journal of Nuclear Medicine and Molecular Imaging.
F. Baldanti,
L. Varani,
L. Simonelli,
2023,
Global challenges.
S. Dakhel,
D. Neri,
Florent Samain,
2021,
Journal of medicinal chemistry.
Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics
K. Schäfers,
F. Büther,
E. Gilardoni,
2023,
The Journal of Nuclear Medicine.